目的 建立住院肿瘤患者应用酮咯酸氨丁三醇评价标准,采用AHP-TOPSIS法对酮咯酸氨丁三醇进行合理性点评。方法 以药品说明书为基础,结合《酮咯酸镇痛专家共识》《癌症疼痛诊疗规范(2018年版)》等制定酮咯酸氨丁三醇合理应用评价细则,并利用AHP赋权TOPSIS法对中国科学院合肥肿瘤医院2022年1月2日-2023年1月9日肿瘤患者使用酮咯酸氨丁三醇注射液的254份病例进行点评。结果 在254份病例中,0.7 ≤ C_i<0.8的病例有13份,占比5.12%;0.6 ≤ C_i<0.7的病例有5份,占比1.97%;C_i<0.6的病例有236份,占比高达92.91%。结论 中国科学院合肥肿瘤医院应用酮咯酸氨丁三醇总体合理性有待进一步提高,应制定对应的干预措施,合理规范使用酮咯酸氨丁三醇,保障患者的生命安全。

Objective To establish evaluation criteria of ketorolac tromethamine for inpatients with tumor, and the to evaluate rationality of ketorolac tromethamine by AHP-TOPSIS method. Methods Based on the drug instructions, combined with the "Expert Consensus on Ketorolac Analgesia" and "Cancer Pain Diagnosis and Treatment Specification (2018 Edition)", the detailed evaluation rules for the rational application of ketorolac tromethamine were formulated, and the AHP weighted TOPSIS method was used to evaluate 254 cases of cancer patients using Ketorolac Tromethamine Injection in Hefei Cancer Hospital, Chinese Academy of Sciences from January 2, 2022 to January 9, 2023. Results Among 254 cases, 13 cases of 0.7 ≤ C_i < 0.8 accounted for 5.12%, 5 cases of 0.6 ≤ C_i < 0.7 accounted for 1.97%, and 236 cases of C_i < 0.6 accounted for 92.91%. Conclusion The overall rationality of the application of ketorolac tromethamine in Hefei Cancer Hospital, Chinese Academy of Sciences needs to be further improved. Corresponding intervention measures should be formulated to rationally regulate the use of ketorolac tromethamine to ensure the safety of patients.

R971

国家自然科学基金资助项目(81703826)